Fate Therapeutics (FATE) Cash from Investing Activities (2012 - 2026)

Fate Therapeutics has reported Cash from Investing Activities for 15 years, with the latest figure at $23.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 44.73% year-over-year to $23.6 million; the trailing twelve-month figure through Mar 2026 stood at $92.1 million (up 145.04% YoY), and the FY2025 full-year result was $111.2 million, up 809.85% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $23.6 million, down from $27.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $80.4 million in Q3 2022, with the low at -$53.4 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged $25.1 million across 5 years, with a median of $24.8 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 3036.37% — and 2024, when it sank 260.92%.
• Fate Therapeutics' Cash from Investing Activities stood at $53.1 million in 2022, then fell by 14.61% to $45.4 million in 2023, then plunged by 49.69% to $22.8 million in 2024, then increased by 21.1% to $27.6 million in 2025, then retreated by 14.63% to $23.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $23.6 million (Q1 2026), $27.6 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.